• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arvinas, Inc. - Common Stock (NQ:ARVN)

    8.225 +0.475 (+6.13%)
    Streaming Delayed Price Updated: 3:24 PM EDT, Sep 26, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,856,042
    Open 7.800
    Bid (Size) 8.220 (9)
    Ask (Size) 8.230 (9)
    Prev. Close 7.750
    Today's Range 7.730 - 8.270
    52wk Range 5.900 - 29.61
    Shares Outstanding 73,200,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
    From Arvinas Inc.
    Via GlobeNewswire
    What 4 Analyst Ratings Have To Say About Arvinas
     
    Via Benzinga

    Performance

    YTD
    -56.5%
    -56.5%
    1 Month
    +9.1%
    +9.1%
    3 Month
    +5.4%
    +5.4%
    6 Month
    +2.3%
    +2.3%
    1 Year
    -65.2%
    -65.2%

    More News

    Read More
    Arvinas to Participate in Upcoming Investor Conferences
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
    From Arvinas Inc.
    Via GlobeNewswire
    Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach
    Via Stocktwits
    Earnings Scheduled For August 6, 2025
    Via Benzinga
    What Analysts Are Saying About Arvinas Stock
    Via Benzinga
    Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates
    Via Chartmill
    Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
    From Arvinas Inc.
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
    From Arvinas Inc.
    Via GlobeNewswire
    Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
    From FN Media Group LLC
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
    From Pomerantz LLP
    Via GlobeNewswire
    Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval
    Via Benzinga
    Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
    From Arvinas Inc.
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
    From Pomerantz LLP
    Via GlobeNewswire
    SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
    From Arvinas Inc.
    Via GlobeNewswire
    Arvinas to Present at Jefferies Global Healthcare Conference
    From Arvinas Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Arvinas, Inc. - Common Stock publicly traded?
    Yes, Arvinas, Inc. - Common Stock is publicly traded.
    What exchange does Arvinas, Inc. - Common Stock trade on?
    Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Arvinas, Inc. - Common Stock?
    The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
    What is the current price of Arvinas, Inc. - Common Stock?
    The current price of Arvinas, Inc. - Common Stock is 8.225
    When was Arvinas, Inc. - Common Stock last traded?
    The last trade of Arvinas, Inc. - Common Stock was at 09/26/25 03:24 PM ET
    What is the market capitalization of Arvinas, Inc. - Common Stock?
    The market capitalization of Arvinas, Inc. - Common Stock is 602.07M
    How many shares of Arvinas, Inc. - Common Stock are outstanding?
    Arvinas, Inc. - Common Stock has 602M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.